Yiɣi chaŋ yɛligu maŋamaŋa puuni

Glucagon-like peptide-1 receptor agonist

Pahimi soya
Diyila Dagbani Wikipedia

Glucagon-like peptide-1 receptor agonists (GLP-1-RA) nyɛla tim tibu pubu balibu (medications) ka bɛ mali li tibiri "type 2 diabetes" mini puli piribu "obesity".[1] ADA kali li mi m-pahi tuuli tima din tu ni di ti type 2 diabetes nima ban ni tooi gbaai doro kamani "atherosclerotic cardiovascular disease" zaŋ kana yuuni 2022.[2] Di shɛŋa chibiri ningbungbaŋ ka shɛli vandi noli ni.[1]

Di barinanima shɛŋa n-nyɛ "nausea", tiri ka nyera, ni puuni biɛrim.[3] Di dii bi filindi ningbuna ni sichiri; amaa dini tooi "pancreatitis" bee "gastroparesis" na.[4][1][5] Binkɔbiri ni tooi mali thyroid C-cell tumors.[2] Paɣ'puhinima bi tu ni bi zaŋli voli.[4]Di tirila GLP-1 receptor yaa.[1] Di pahirila "insulin" yihibu ka boori glucagon zaŋ chaŋ shikiri pam polo; ka bi waɣisiri puli yom.[1]

Tuuli GLP-1-RA, exenatide, zaŋ tum tima tuma saɣiti daa niŋla United States yuuni 2005.[1] Zaŋ kana yuuni 2022 di daa niŋ liɣiri pam United States, ka dari Kamani 1,000 USD goli kam ni.[2] Di zaɣ'pala yina ni "long acting insulin".[2] Di daa dami pooi Silimiin yuuni 2023 ka di nyɛla ban borili n daa nabigi.[6][7]

  1. 1 2 3 4 5 6 Nauck, MA (April 2021). "GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.". Molecular metabolism 46: 101102. DOI:10.1016/j.molmet.2020.101102. PMID 33068776.
  2. 1 2 3 4 American Diabetes Association Professional Practice Committee (January 2022). "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022". Diabetes Care 45 (Suppl 1): S125–S143. DOI:10.2337/dc22-S009. PMID 34964831.
  3. ↑ Iqbal, J (June 2022). "Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.". Obesity reviews : an official journal of the International Association for the Study of Obesity 23 (6): e13435. DOI:10.1111/obr.13435. PMID 35194917.
  4. 1 2 Collins, Logan; Costello, Ryan A. (2023). "Glucagon-like Peptide-1 Receptor Agonists". StatPearls. StatPearls Publishing. Archived from the original on 8 March 2023. Retrieved 23 July 2023.
  5. ↑ Young, Clipper F. (1 August 2020). "Diabetic Gastroparesis: A Review". Diabetes Spectrum 33 (3): 290–297. DOI:10.2337/ds19-0062.
  6. ↑ Jankovic, Saša (28 June 2023). Government declares 'national shortage' of GLP-1 receptor agonists for type 2 diabetes until 2024.
  7. ↑ Cruz, Jace (11 July 2023). "Global Shortage of Diabetes Medicine 'Ozempic' Could Persist for a Longer Time, Experts Claim". https://www.techtimes.com/articles/293650/20230711/global-shortage-diabetes-medication-ozempic-persist-longer-time-experts-claim.htm.
Di yila "https://dag.wikipedia.org/w/index.php?title=Glucagon-like_peptide-1_receptor_agonist&oldid=99298"